MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202641089183 A) filed by Srinivas University; Institute Of Engineering And Technology on July 22, 2026, for Design, Synthesis, Characterization And Biological Evaluation Of Napthalimide Based Shiff Bases.
Inventors include Dr. Praveen B. M.; Dr. Shivaraja G.; Dr. Lokesh K S; Mr. Shailesh Shetty S; Ankitha K; Harish Kunder; Madhavi Gatty; Srinivas Pm; and Dr. Naveen Kumar J R.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: ABSTRACT “DESIGN, SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL EVALUATION OF NAPTHALIMIDE BASED SHIFF BASES ” The present invention relates to novel naphthalimide-based Schiff base derivatives, their preparation process, and their applications as multifunctional biologically active compounds. The invention provides a new class of chemically modified naphthalimide compounds containing an azomethine (–CH=N–) linkage, synthesized through condensation of amino-substituted naphthalimide intermediates with substituted aromatic aldehydes. The process involves the preparation of naphthalimide intermediates from 3-nitro-1,8-naphthalic anhydride, followed by reduction of the nitro functionality and subsequent Schiff base formation with substituted salicylaldehydes. The synthesized compounds are characterized by spectroscopic and analytical techniques including FT-IR, 1H NMR, 13C NMR, and mass spectrometry. The compounds of the invention exhibit promising biological properties including antimicrobial, antioxidant, anti-inflammatory, and anticancer activities. The synthesized derivatives demonstrate antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa, along with antifungal activity against Candida albicans and Aspergillus niger. The compounds also exhibit free radical scavenging activity through DPPH and nitric oxide assays and demonstrate inhibition of protein denaturation associated with anti-inflammatory activity. Further, selected compounds show cytotoxic activity against cancer cell lines including MIAPaCa-2, HCT116, A549, and HeLa, indicating their potential application in pharmaceutical development. The invention provides novel naphthalimide-based chemical entities with a simple synthetic approach and multifunctional therapeutic potential for use in the development of antimicrobial, antioxidant, anti-inflammatory, and anticancer agents.
Disclaimer: Curated by HT Syndication.
